Checkpoint Therapeutics CEO James F. Oliviero III Sells Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III has sold 9,233 shares of the company’s stock in a transaction that took place on Friday, February 7th. The shares were sold at an average price of $3.41 each, resulting in a total transaction amount of $31,484.53. After this sale, Oliviero III continues to hold 3,785,350 shares, which are valued at about $12,908,043.50. This represents a 0.24% reduction in his ownership stake in the company. The details of the transaction were disclosed in a filing with the Securities and Exchange Commission (SEC), and further information can be found through their official site.

Checkpoint Therapeutics Stock Performance

On Wednesday, Checkpoint Therapeutics' stock opened at $3.13. The company has a market capitalization of $152.84 million, with a price-to-earnings (P/E) ratio of -1.70 and a beta of 1.36. Checkpoint’s 50-day moving average price is $3.39, while the 200-day moving average is $2.99. Over the past year, the stock has experienced a low of $1.38 and a high of $4.50.

Checkpoint Therapeutics announced its earnings results on November 12th, reporting earnings per share (EPS) of ($0.23) for the quarter. This figure fell short of the consensus estimate of ($0.15) by $0.08. Analysts predict that Checkpoint Therapeutics will report an EPS of -0.94 for the current year.

Institutional Investors' Involvement

Recent activity among institutional investors in Checkpoint Therapeutics has seen several new positions acquired. Virtu Financial LLC took a position worth about $30,000 during the third quarter. SBI Securities Co. Ltd. and PUREfi Wealth LLC have also purchased shares during the fourth quarter, each investing approximately $32,000. Bartlett & Co. Wealth Management LLC significantly increased its holdings by 375.0%, now owning 19,000 shares valued at $61,000. Charles Schwab Investment Management Inc. also acquired a new position valued at $64,000. Currently, institutional investors and hedge funds hold around 22.00% of the company’s stock.

Recent Analyst Ratings

Analysts have given mixed feedback on CKPT shares. HC Wainwright reaffirmed a “buy” rating with a price target of $20.00 in a report dated December 16th. D. Boral Capital has initiated coverage with a “buy” rating and set a price target of $9.00 on January 13th. Meanwhile, Lake Street Capital raised their target price from $4.00 to $7.00 while maintaining a “buy” rating in December.

Company Overview

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company. It specializes in the development and commercialization of innovative treatments for solid tumor cancers both in the United States and internationally. The company’s primary product candidate is Cosibelimab, which is undergoing Phase 1 clinical trials aimed at treating patients with specific recurrent or metastatic cancers. Another candidate, CK-302, is in preclinical trials focusing on hematological malignancies and solid tumors.

checkpoint, therapeutics, shares